Statement Of Financial Position [Abstract]

Hyloris Pharmaceuticals SA - Filing #3166143

Concept As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
Statement of financial position [abstract]
Assets [abstract]
Property, plant and equipment
429,000 EUR
176,000 EUR
Intangible assets other than goodwill
3,828,000 EUR
3,607,000 EUR
Investments accounted for using equity method
3,801,000 EUR
3,948,000 EUR
Cash and cash equivalents
30,406,000 EUR
33,457,000 EUR
50,012,000 EUR
Assets
47,681,000 EUR
60,728,000 EUR
Equity and liabilities [abstract]
Equity [abstract]
Issued capital
140,000 EUR
140,000 EUR
Share premium
121,513,000 EUR
121,513,000 EUR
Other reserves
476,000 EUR
476,000 EUR
Equity
39,069,000 EUR
80,761,000 EUR
476,000 EUR
121,513,000 EUR
140,000 EUR
2,162,000 EUR
4,460,000 EUR
53,909,000 EUR
1,136,000 EUR
140,000 EUR
121,513,000 EUR
476,000 EUR
476,000 EUR
1,622,000 EUR
1,136,000 EUR
4,460,000 EUR
121,513,000 EUR
1,622,000 EUR
65,381,000 EUR
64,246,000 EUR
140,000 EUR
55,045,000 EUR
4,460,000 EUR
54,805,000 EUR
476,000 EUR
48,056,000 EUR
3,827,000 EUR
103,693,000 EUR
2,391,000 EUR
129,000 EUR
Liabilities [abstract]
Liabilities
8,613,000 EUR
6,819,000 EUR
Equity and liabilities
47,681,000 EUR
60,728,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.